Skip to main content
Top
Published in: Pediatric Drugs 5/2011

01-10-2011 | Therapy In Practice

Drug Treatment of Hypertensive Crisis in Children

Author: Christopher A. Thomas, PharmD

Published in: Pediatric Drugs | Issue 5/2011

Login to get access

Abstract

Hypertensive crisis is a relatively rare event and is associated with significant morbidity and mortality in adults and pediatric patients alike. Rapid, safe, and effective treatment is imperative to alleviate immediate presenting clinical symptoms, prevent devastating morbidity, preserve long-term quality of life, and prevent mortality. Many medications in the hypertensive crisis arsenal have been used for nearly half a century. Nearly all treatment options have been utilized in children for decades, yet reliable data and sound clinical literature remain elusive. Every agent considered to be a first-line, second-line, or adjunctive option has yet to be evaluated in a randomized controlled trial in pediatric patients. With a paucity of clinical data to form evidence-based decisions, the clinician must rely entirely on the extrapolation from adult data and small retrospective studies, case series, and case reports of medication use in pediatric patients.
Although more research in the treatment of pediatric hypertensive crisis is desperately needed, current practice demands a sharp knowledge of the pediatric clinical literature and pharmacology in this area as an essential tool to consistently improve patient outcomes with respect to morbidity and mortality.
Literature
1.
2.
go back to reference Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24(6): 1101–12PubMedCrossRef Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24(6): 1101–12PubMedCrossRef
3.
go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–76CrossRef National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555–76CrossRef
4.
go back to reference Patel HP, Mitsnefes M. Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 2005; 17: 210–4PubMedCrossRef Patel HP, Mitsnefes M. Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 2005; 17: 210–4PubMedCrossRef
5.
go back to reference Constantine E, Linakis J. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care 2005; 21: 391–9PubMedCrossRef Constantine E, Linakis J. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care 2005; 21: 391–9PubMedCrossRef
6.
go back to reference Fivush B, Neu A, Furth S. Acute hypertensive crises in children: emergencies and urgencies. Curr Opin Pediatr 1997; 9: 233–6PubMedCrossRef Fivush B, Neu A, Furth S. Acute hypertensive crises in children: emergencies and urgencies. Curr Opin Pediatr 1997; 9: 233–6PubMedCrossRef
7.
go back to reference Porto I. Hypertensive emergencies in children. J Pediatr Health Care 2000; 14: 312–9PubMed Porto I. Hypertensive emergencies in children. J Pediatr Health Care 2000; 14: 312–9PubMed
8.
go back to reference Suresh S, Mahajan P, Kamat D. Emergency management of pediatric hypertension. Clin Pediatr 2005; 44: 739–45CrossRef Suresh S, Mahajan P, Kamat D. Emergency management of pediatric hypertension. Clin Pediatr 2005; 44: 739–45CrossRef
9.
10.
11.
12.
go back to reference Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs 2008; 68(3): 283–97PubMedCrossRef Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs 2008; 68(3): 283–97PubMedCrossRef
13.
go back to reference Gordillo-Paniagua G, Velasques-Jones L, Martini R, et al. Sodium nitroprusside treatment of severe arterial hypertension in children. J Pediatr 1975; 87(5): 799–802PubMedCrossRef Gordillo-Paniagua G, Velasques-Jones L, Martini R, et al. Sodium nitroprusside treatment of severe arterial hypertension in children. J Pediatr 1975; 87(5): 799–802PubMedCrossRef
14.
go back to reference Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984; 9: 239–51PubMedCrossRef Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984; 9: 239–51PubMedCrossRef
15.
go back to reference Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 1998; 19(2): 99–122PubMedCrossRef Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 1998; 19(2): 99–122PubMedCrossRef
16.
go back to reference Benitz WE, Malachowski N, Cohen RS, et al. Use of sodium nitroprusside in neonates: efficacy and safety. J Pediatr 1984; 106(1): 102–10 Benitz WE, Malachowski N, Cohen RS, et al. Use of sodium nitroprusside in neonates: efficacy and safety. J Pediatr 1984; 106(1): 102–10
17.
go back to reference Kunathai S, Sholler GF, Celermajer JM, et al. Nitroprusside in children after cardiopulmonary bypass: a study of thiocyanate toxicity. Pediatr Cardiol 1989; 10: 121–4PubMedCrossRef Kunathai S, Sholler GF, Celermajer JM, et al. Nitroprusside in children after cardiopulmonary bypass: a study of thiocyanate toxicity. Pediatr Cardiol 1989; 10: 121–4PubMedCrossRef
18.
go back to reference Lopez-Herce J, Borrego R, Bustinza A, et al. Elevated carboxyhemoglobin associated with sodium nitroprusside treatment. Intensive Care Med 2005; 31(9): 1235–8PubMedCrossRef Lopez-Herce J, Borrego R, Bustinza A, et al. Elevated carboxyhemoglobin associated with sodium nitroprusside treatment. Intensive Care Med 2005; 31(9): 1235–8PubMedCrossRef
19.
go back to reference Meyer S, Baghai A, Sailer NL, et al. Lactic acidosis caused by sodium nitroprusside in a newborn with congenital heart disease. Eur J Pediatr 2005; 164(4): 253–4PubMedCrossRef Meyer S, Baghai A, Sailer NL, et al. Lactic acidosis caused by sodium nitroprusside in a newborn with congenital heart disease. Eur J Pediatr 2005; 164(4): 253–4PubMedCrossRef
21.
go back to reference Przybylo HJ, Stevenson GW, Schanbacher P, et al. Sodium nitroprusside metabolism in children during hypothermic cardiopulmonary bypass. Anesth Analg 1995; 81(5): 952–6PubMed Przybylo HJ, Stevenson GW, Schanbacher P, et al. Sodium nitroprusside metabolism in children during hypothermic cardiopulmonary bypass. Anesth Analg 1995; 81(5): 952–6PubMed
22.
go back to reference Moffett BS, Price JF. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother 2008; 42(11): 1600–4PubMedCrossRef Moffett BS, Price JF. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother 2008; 42(11): 1600–4PubMedCrossRef
23.
go back to reference Cole PV, Vesey CJ. Sodium thiosulphate decreases blood cyanide concentrations after the infusion of sodium nitroprusside. Br J Anaesth 1987; 59: 531–5PubMedCrossRef Cole PV, Vesey CJ. Sodium thiosulphate decreases blood cyanide concentrations after the infusion of sodium nitroprusside. Br J Anaesth 1987; 59: 531–5PubMedCrossRef
24.
go back to reference Schulz V, Roth B. Detoxification of cyanide in a newborn child. Klin Wochenschrift 1982; 60: 527–8CrossRef Schulz V, Roth B. Detoxification of cyanide in a newborn child. Klin Wochenschrift 1982; 60: 527–8CrossRef
25.
go back to reference Vesey CJ, Krapez JR, Varley JG, et al. The antidotal action of thiosulfate following acute nitroprusside infusion in dogs. Anesthesiology 1985; 62: 415–21PubMedCrossRef Vesey CJ, Krapez JR, Varley JG, et al. The antidotal action of thiosulfate following acute nitroprusside infusion in dogs. Anesthesiology 1985; 62: 415–21PubMedCrossRef
26.
go back to reference Nitropress (Sodium Nitroprusside) injection: solution package insert. Lake Forest (IL): Hospira, Inc., 2004 Dec Nitropress (Sodium Nitroprusside) injection: solution package insert. Lake Forest (IL): Hospira, Inc., 2004 Dec
27.
go back to reference Thomas C, Svehla L, Moffett BS. Sodium nitroprusside induced cyanide toxicity in pediatric patients. Expert Opin Drug Saf 2009; 8(5): 599–602PubMedCrossRef Thomas C, Svehla L, Moffett BS. Sodium nitroprusside induced cyanide toxicity in pediatric patients. Expert Opin Drug Saf 2009; 8(5): 599–602PubMedCrossRef
28.
go back to reference Treluyer JM, Hubert P, Jouvet P, et al. Intravenous nicardipine in hypertensive children. Eur J Pediatr 1993; 152: 712–4PubMedCrossRef Treluyer JM, Hubert P, Jouvet P, et al. Intravenous nicardipine in hypertensive children. Eur J Pediatr 1993; 152: 712–4PubMedCrossRef
29.
go back to reference Flynn JT, Mottes TA, Brophy PD, et al. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 2001; 139: 38–43PubMedCrossRef Flynn JT, Mottes TA, Brophy PD, et al. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 2001; 139: 38–43PubMedCrossRef
30.
go back to reference Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Int Care Med 2000; 26: 956–8CrossRef Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Int Care Med 2000; 26: 956–8CrossRef
31.
go back to reference Nakagawa TA, Sartori SC, Morris A, et al. Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 2004; 25: 26–30PubMedCrossRef Nakagawa TA, Sartori SC, Morris A, et al. Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 2004; 25: 26–30PubMedCrossRef
32.
go back to reference Michael J, Groshong T, Tobias JD. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998; 12: 40–2PubMedCrossRef Michael J, Groshong T, Tobias JD. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998; 12: 40–2PubMedCrossRef
33.
go back to reference Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child 1997; 76: F126–7 Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child 1997; 76: F126–7
34.
go back to reference McBride BF, White CM, Campbell M, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother 2003; 37: 667–70PubMedCrossRef McBride BF, White CM, Campbell M, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother 2003; 37: 667–70PubMedCrossRef
35.
go back to reference Tenney F, Sakarcan A. Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 2000; 35(5): E20PubMedCrossRef Tenney F, Sakarcan A. Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 2000; 35(5): E20PubMedCrossRef
36.
go back to reference Immink RV, van den Born BH, van Montfrans GA, et al. Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 2008; 52: 236–40PubMedCrossRef Immink RV, van den Born BH, van Montfrans GA, et al. Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 2008; 52: 236–40PubMedCrossRef
37.
go back to reference Labetalol hydrochloride injection: package insert. Bedford (OH): Bedford Laboratories, 2000 Jun Labetalol hydrochloride injection: package insert. Bedford (OH): Bedford Laboratories, 2000 Jun
38.
go back to reference Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 2011; 12(1): 28–32PubMedCrossRef Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 2011; 12(1): 28–32PubMedCrossRef
39.
go back to reference Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 1992; 120: 140–4PubMedCrossRef Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 1992; 120: 140–4PubMedCrossRef
40.
go back to reference Bojar RM, Weiner B, Cleveland RJ. Intravenous labetalol for the control of hypertension following repair of coarctation of the aorta. Clin Cardiol 1988; 11: 639–41PubMedCrossRef Bojar RM, Weiner B, Cleveland RJ. Intravenous labetalol for the control of hypertension following repair of coarctation of the aorta. Clin Cardiol 1988; 11: 639–41PubMedCrossRef
41.
go back to reference Wintergerst KA, Buckingham B, Gandrud L, et al. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics 2006; 118: 173–9PubMedCrossRef Wintergerst KA, Buckingham B, Gandrud L, et al. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics 2006; 118: 173–9PubMedCrossRef
42.
go back to reference Adamson PC, Rhodes LA, Saul JP, et al. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 2006; 27: 420–7PubMedCrossRef Adamson PC, Rhodes LA, Saul JP, et al. The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 2006; 27: 420–7PubMedCrossRef
43.
go back to reference Tabbutt S, Nicolson SC, Adamson PC, et al. The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg 2008; 136(2): 321–8PubMedCrossRef Tabbutt S, Nicolson SC, Adamson PC, et al. The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg 2008; 136(2): 321–8PubMedCrossRef
44.
go back to reference Wiest DB, Trippel DL, Gillette PC, et al. Pharmacokinetics of esmolol in children. Clin Pharmacol Ther 1991; 49(6): 618–23PubMedCrossRef Wiest DB, Trippel DL, Gillette PC, et al. Pharmacokinetics of esmolol in children. Clin Pharmacol Ther 1991; 49(6): 618–23PubMedCrossRef
45.
go back to reference Vincent RN, Click LA, Williams HM, et al. Esmolol as an adjunct in the treatment of systemic hypertension after operative repair of coarctation of the aorta. Am J Cardiol 1990; 65(13): 941–3PubMedCrossRef Vincent RN, Click LA, Williams HM, et al. Esmolol as an adjunct in the treatment of systemic hypertension after operative repair of coarctation of the aorta. Am J Cardiol 1990; 65(13): 941–3PubMedCrossRef
46.
go back to reference Trippel DL, Wiest DB, Gillette PC. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 1991; 119(1): 142–7PubMedCrossRef Trippel DL, Wiest DB, Gillette PC. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 1991; 119(1): 142–7PubMedCrossRef
47.
go back to reference Cuneo BF, Zales VR, Blahunka PC, et al. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent in children. Pediatr Cardiol 1994; 15(6): 296–301PubMedCrossRef Cuneo BF, Zales VR, Blahunka PC, et al. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent in children. Pediatr Cardiol 1994; 15(6): 296–301PubMedCrossRef
48.
go back to reference Wiest DB, Garner SS, Uber WE, et al. Esmolol for the management of pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg 1998; 115: 890–7PubMedCrossRef Wiest DB, Garner SS, Uber WE, et al. Esmolol for the management of pediatric hypertension after cardiac operations. J Thorac Cardiovasc Surg 1998; 115: 890–7PubMedCrossRef
49.
go back to reference Esmolol hydrochloride: package insert. Bedford (OH): Bedford Laboratories, 2008 Aug Esmolol hydrochloride: package insert. Bedford (OH): Bedford Laboratories, 2008 Aug
50.
go back to reference Jacobs M. Mechanism of action of hydralazine on vascular smooth muscle. Biochem Pharmacol 1984; 33(18): 2915–9PubMedCrossRef Jacobs M. Mechanism of action of hydralazine on vascular smooth muscle. Biochem Pharmacol 1984; 33(18): 2915–9PubMedCrossRef
51.
go back to reference Bang L, Nielsen-Kudsk JE, Gruhn N, et al. Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels. Eur J Pharmacol 1998; 361(1): 43–9PubMedCrossRef Bang L, Nielsen-Kudsk JE, Gruhn N, et al. Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels. Eur J Pharmacol 1998; 361(1): 43–9PubMedCrossRef
52.
go back to reference Knowles HJ, Tian Y, Mole DR, et al. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1 alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004; 95(2): 162–9PubMedCrossRef Knowles HJ, Tian Y, Mole DR, et al. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1 alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004; 95(2): 162–9PubMedCrossRef
53.
go back to reference Endo H, Shiraishi H, Yanagisawa M. Afterload reduction by hydralazine in children with a ventricular septal defect as determined by aortic input impedance. Cardiovasc Drugs Ther 1994; 8(1): 161–6PubMedCrossRef Endo H, Shiraishi H, Yanagisawa M. Afterload reduction by hydralazine in children with a ventricular septal defect as determined by aortic input impedance. Cardiovasc Drugs Ther 1994; 8(1): 161–6PubMedCrossRef
54.
go back to reference Houston MC. Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration: a review. Ann Intern Med 1986; 146: 586–9CrossRef Houston MC. Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration: a review. Ann Intern Med 1986; 146: 586–9CrossRef
55.
go back to reference Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 2002; 17(9): 748–53PubMedCrossRef Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 2002; 17(9): 748–53PubMedCrossRef
56.
go back to reference Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000; 93(3): 287–93PubMed Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000; 93(3): 287–93PubMed
57.
go back to reference Miyashita Y, Petereson D, Rees JM, et al. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens 2010; 12: 850–5CrossRef Miyashita Y, Petereson D, Rees JM, et al. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens 2010; 12: 850–5CrossRef
58.
go back to reference Johnson CE, Jacobsen PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother 1997; 31: 704–7PubMed Johnson CE, Jacobsen PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother 1997; 31: 704–7PubMed
59.
go back to reference Strife CF, Quinlan M, Waldo FB, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986; 78(5): 861–5PubMed Strife CF, Quinlan M, Waldo FB, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986; 78(5): 861–5PubMed
60.
go back to reference Pennisi AJ, Takahashi M, Bernstein BH. Minoxidil therapy in children with severe hypertension. J Pediatr 1977; 90(5): 813–9PubMedCrossRef Pennisi AJ, Takahashi M, Bernstein BH. Minoxidil therapy in children with severe hypertension. J Pediatr 1977; 90(5): 813–9PubMedCrossRef
61.
go back to reference Lopez-Herce J, Dorao P, de la Oliva P, et al. Dosage of nifedipine in hypertensive crises of infants and children. Eur J Pediatr 1989; 149: 136–7PubMedCrossRef Lopez-Herce J, Dorao P, de la Oliva P, et al. Dosage of nifedipine in hypertensive crises of infants and children. Eur J Pediatr 1989; 149: 136–7PubMedCrossRef
62.
go back to reference Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens 2007; 9: 399–405CrossRef Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens 2007; 9: 399–405CrossRef
63.
go back to reference Lönnqvist PA, Bergendahl HTG, Eksborg S. Pharmacokinetics of clonidine after rectal administration in children. Anesthesiology 1994; 81: 1097–101PubMedCrossRef Lönnqvist PA, Bergendahl HTG, Eksborg S. Pharmacokinetics of clonidine after rectal administration in children. Anesthesiology 1994; 81: 1097–101PubMedCrossRef
64.
go back to reference Almenrader N, Larsson P, Passariello M, et al. Absorption pharmacokinetics of clonidine nasal drops in children. Pediatr Anesth 2009; 19: 257–61CrossRef Almenrader N, Larsson P, Passariello M, et al. Absorption pharmacokinetics of clonidine nasal drops in children. Pediatr Anesth 2009; 19: 257–61CrossRef
65.
go back to reference Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15: 302–16PubMedCrossRef Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15: 302–16PubMedCrossRef
66.
go back to reference Houtman P. Management of hypertensive emergencies in children. Pediatr Perinat Drug Ther 2005; 5(3): 107–10CrossRef Houtman P. Management of hypertensive emergencies in children. Pediatr Perinat Drug Ther 2005; 5(3): 107–10CrossRef
67.
go back to reference Herbert CJ, Vidt DG. Hyertensive crises. Prim Care Clin Office Pract 2008; 35: 475–87CrossRef Herbert CJ, Vidt DG. Hyertensive crises. Prim Care Clin Office Pract 2008; 35: 475–87CrossRef
69.
go back to reference Griebenow R, Kaufmann W, Krämer L, et al. Isradipine: a new calcium antagonist with strong vasodilatory but negligible cardiodepressive effects. J Cardiovasc Pharmacol 1990; 15Suppl. 1: S84–6PubMed Griebenow R, Kaufmann W, Krämer L, et al. Isradipine: a new calcium antagonist with strong vasodilatory but negligible cardiodepressive effects. J Cardiovasc Pharmacol 1990; 15Suppl. 1: S84–6PubMed
70.
go back to reference Gottlieb TB, Thomas RC, Chidsey CA. Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 1972; 13: 436–41PubMed Gottlieb TB, Thomas RC, Chidsey CA. Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 1972; 13: 436–41PubMed
71.
go back to reference Levinson ML, Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. Am J Hosp Pharm 1992; 49(1): 122–5PubMed Levinson ML, Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. Am J Hosp Pharm 1992; 49(1): 122–5PubMed
72.
go back to reference MacDonald JL, Johnson CE, Jacobsen P. Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 1994; 51: 2409–11PubMed MacDonald JL, Johnson CE, Jacobsen P. Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 1994; 51: 2409–11PubMed
73.
Metadata
Title
Drug Treatment of Hypertensive Crisis in Children
Author
Christopher A. Thomas, PharmD
Publication date
01-10-2011
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 5/2011
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/11592130-000000000-00000

Other articles of this Issue 5/2011

Pediatric Drugs 5/2011 Go to the issue